Anti-tumor necrosis factor alpha treatment does not influence serum levels of the markers associated with radiographic progression in ankylosing spondylitis

Objectives: The study aimed to determine the levels of change of the markers related to radiographic progression, such as Dickkopf-1 (DKK-1), sclerostin (SOST), bone morphogenetic protein (BMP)-2 and -4, and interleukin (IL)-17 and -23, in ankylosing spondyloarthritis (AS) during anti-tumor necrosis...

Full description

Saved in:
Bibliographic Details
Published in:Archives of rheumatology 2023-03, Vol.38 (1), p.148-155
Main Authors: Ozdemirel, Ali Erhan, Guven, Serdar Can, Doganci, Alper, Surmeli, Zuhre Sari, Ozyuvali, Ayla, Kurt, Mehmet, Rustemova, Diana, Hassan, Selin, Sayin, Ayse Peyman Yalcin, Tutkak, Huseyin, Ataman, Sebnem
Format: Article
Language:English
Subjects:
Ankylosing spondylitis
Antiarthritic agents
Bone morphogenetic proteins
Development and progression
Diagnosis
Drug therapy
Interleukins
Medical research
Medicine, Experimental
Necrosis
Original
Tumor necrosis factor
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives: The study aimed to determine the levels of change of the markers related to radiographic progression, such as Dickkopf-1 (DKK-1), sclerostin (SOST), bone morphogenetic protein (BMP)-2 and -4, and interleukin (IL)-17 and -23, in ankylosing spondyloarthritis (AS) during anti-tumor necrosis factor alpha (TNF-[alpha]) treatment. Patients and methods: Fifty-three anti-TNF-[alpha] naive AS patients (34 males, 19 females; median: 38 years; range, 20 to 52 years) refractory to conventional treatments meeting the modified New York criteria or Assessment of Spondylo Arthritis International Society classification criteria were enrolled to this cross-sectional, controlled study between October 2015 and January 2017. Fifty healthy volunteers (35 males, 15 females; median: 36 years; range, 18 to 55 years) with similar age and sex characteristics were recruited. Serum DKK-1, BMP-2, BMP-4, SOST, IL-17, and IL-23 levels were measured in both groups. The serum levels of the markers were measured again after about two years (mean follow-up duration of 21.7[+ or -]6.4 months) in AS patients who started anti-TNF-[alpha] treatment. Demographic, clinical characteristics, and laboratory parameters were recorded. The disease activity at the time of inclusion was assessed through the Bath Ankylosing Spondylitis Disease Activity Index. Results: Serum DKK-1, SOST, IL-17, and IL-23 levels in the AS group before anti-TNF-[alpha] treatment were significantly higher compared to the control group (p
ISSN:2148-5046
2618-6500
DOI:10.46497/ArchRheumatol.2023.9974